Smith & Nephew and J&J: Governance, Not Price, Sinks Deals

When a merger blows up, the instinct is to ask whether the price was wrong. The Smith & Nephew and Johnson & Johnson story points somewhere less comfortable: the reported cause is not money at all, but a question of who gets the corner office.

The deal reportedly died over a name, not a number

According to a Financial Times report relayed by Reuters, Smith & Nephew's talks to combine with J&J's orthopaedics division fell apart after the London-listed group refused to agree to a former CEO leading the merged business. Investing.com's summary of the report adds that Smith & Nephew said it would only agree if its own boss, Deepak Nath, stayed on as CEO.

Two caveats. These were talks, not a signed agreement, and the reports we have rest on people familiar with the matter, not on a company statement. The reports we have also don't describe the financial terms in any reliable detail, and one outlet's headline cites a $34 billion figure that we can't verify elsewhere, so we won't rely on a number. What the sources do agree on is the cause, and that matters more than the amount.

The sticking point was control, and that's the norm

A combination like this is a negotiation about who is buying whom, even when it's dressed up as a merger of equals. Price can often be bridged: a bit more cash, a few more shares, a contingent payment. A chief executive's job can't be split. Either Smith & Nephew's leader runs the combined company or someone else does, and each side's board has to explain that choice to shareholders.

In our view, that is why leadership disputes show up so often at the final stage. By then the valuation work is usually done. What remains is the question that reveals who actually holds the leverage. Smith & Nephew's reported refusal reads like a company that decided control over its own direction was worth more than whatever the deal offered. We think that is a defensible choice, but it is also a choice that has a cost.

Smith & Nephew may have less room to be picky than it looks

Here the context is uncomfortable. The company has had a bumpy year. In August it cut its annual revenue growth forecast after missing second-quarter expectations, as it grapples with weak knee implant demand and skin graft prices, and, as Morningstar reported, its shares fell 6.6% to 1,118 pence, the worst performer in the FTSE 100 that day. Two weeks later the shares slipped again on news that the finance chief was leaving.

That doesn't prove the board was wrong to dig in. A management team that has set out a plan targeting more than $1 billion in free cash flow by 2028 has a reason to want to see it through. But it does mean shareholders now hold a company that, according to the reports, walked away from a transformational option while its operating story is still being repaired. Whether that was stubbornness or discipline will be settled by the next few earnings reports, not by this week's headlines. The market's reaction to the collapse isn't in the material we have, so we won't guess at it.

Treat deals like options, not like facts

The practical lesson is for anyone who holds shares in a company rumored to be in merger talks. A deal at the "advanced talks" stage is an option with an expiry date, and the thing that kills it is often not on the term sheet. Ask the questions the price can't answer: who runs the combined company? Where is it headquartered? Who sits on the board? If those are unresolved, the probability of closing is lower than the headline suggests.

This is general reasoning, not a recommendation about any particular stock, and we aren't predicting where Smith & Nephew goes from here. We'd simply say two things. First, don't build a position on the assumption that a deal will happen; if a rumor lifts a share price, that premium can evaporate as quickly as it appeared. Second, judge the company by what it earns on its own. The business was either worth owning before the talks leaked or it wasn't.

Our verdict: the likeliest culprit here isn't greed or a lowball offer but the oldest obstacle in corporate life, which is control. Until a company says something official, the useful stance is to take the report seriously, treat the deal as unfinished, and put your money behind earnings, not headlines.